{"id":959551,"date":"2026-05-07T07:05:26","date_gmt":"2026-05-07T11:05:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-provides-first-quarter-2026-financial-and-corporate-update\/"},"modified":"2026-05-07T07:05:26","modified_gmt":"2026-05-07T11:05:26","slug":"foghorn-therapeutics-provides-first-quarter-2026-financial-and-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-provides-first-quarter-2026-financial-and-corporate-update\/","title":{"rendered":"Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update"},"content":{"rendered":"
\n

\n – FHD-909 (LY4050784) Phase 1 dose-escalation trial on track; preclinical combination data with anti-PD-1 antibody demonstrates potential for robust and durable regression with anti-tumor immune memory\u00a0<\/em>\n <\/p>\n

\n – Selective CBP degrader FHT-171 advancing for the treatment of ER+ breast cancer with IND anticipated in 2027<\/em>\n <\/p>\n

\n -Selective EP300 degraders with potential in multiple myeloma and other hematological malignancies with IND anticipated in 2027<\/em>\n <\/p>\n

\n – Strong balance sheet with cash, cash equivalents, and marketable securities of approximately <\/em>
\n $184 million<\/em>
\n ; cash runway into the first half of 2028<\/em>
\n \n <\/p>\n

WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) — Foghorn\u00ae Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a financial and corporate update in conjunction with the Company\u2019s 10-Q filing for the quarter ended March 31, 2026. With an initial focus in oncology, Foghorn\u2019s Gene Traffic Control\u00ae Platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.<\/p>\n

\u201cOur lead program, FHD-909, continues to advance through dose escalation in collaboration with Lilly. The trial is enriching for NSCLC patients with SMARCA4 mutations, where outcomes remain especially poor and deteriorate with later lines of therapy,\u201d said Adrian Gottschalk, President and Chief Executive Officer of Foghorn Therapeutics. \u201cAt this year\u2019s American Association for Cancer Research (AACR) Annual Meeting, we presented compelling preclinical data demonstrating the potential of FHD-909 in combination with an anti-PD-1 antibody to drive complete, durable tumor regression and anti-tumor immune memory.\u201d<\/p>\n

Mr. Gottschalk continued, \u201cAcross our wholly owned pipeline, we reported new preclinical data highlighting strong anti-tumor activity and tolerability for our Selective CBP degrader FHT-171 in heavily pretreated ER+ breast cancer models, improved safety and efficacy versus clinical benchmark for our Selective EP300 degrader in multiple myeloma, and robust target degradation with potential for oral bioavailability for our cereblon-based selective ARID1B degraders. Together, these programs expand our reach in difficult-to-treat cancers, and we look forward to sharing further progress throughout the year.\u201d<\/p>\n

\n Program Overview and Upcoming Milestones<\/strong>\n <\/p>\n

\n FHD-909 (LY4050784). <\/strong>FHD-909 is a first-in-class oral SMARCA2 selective inhibitor that has demonstrated in preclinical studies to have high selectivity over its closely related paralog SMARCA4, two proteins that are the catalytic engines across all forms of the BAF complex. Selectively blocking SMARCA2 activity is a promising synthetic lethal strategy intended to induce tumor death while sparing healthy cells. SMARCA4 is mutated in up to 10% of NSCLC patients and implicated in a significant number of solid tumors. Across lines of therapy, significant unmet needs remain for patients with SMARCA4 (BRG1)-mutant cancers with both poor response rates and short progression-free survival.<\/p>\n